Anders Svenningsson

Publications
Grants
CV
Public outreach and news

Articles

Article: ANNALS OF NEUROLOGY. 2024;96(4):678-693
COMBAT-MS: A Population-Based Observational Cohort Study Addressing the Benefit-Risk Balance of Multiple Sclerosis Therapies Compared with Rituximab
Piehl F; Alping P; Virtanen S; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Mellergard J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Frisell T
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2024;31(8):e16331
Hypogammaglobulinaemia during rituximab treatment in multiple sclerosis: A Swedish cohort study
Hallberg S; Evertsson B; Lillvall E; Boremalm M; de Flon P; Wang Y; Salzer J; Lycke J; Fink K; Frisell T; Al Nimer F; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL. 2024;10(2):20552173241252566
A comparative study of fatigue and processing speed in patients with multiple sclerosis treated with natalizumab or rituximab
Hellgren J; Strandberg MC; Kallen K; Svenningsson A
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2024;95(2):125-133
Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study
Silfverberg T; Zjukovskaja C; Ljungman P; Nahimi A; Ahlstrand E; Dreimane A; Einarsdottir S; Fagius J; Iacobaeus E; Hagglund H; Lange N; Lenhoff S; Lycke J; Mellergard J; Piehl F; Svenningsson A; Tolf A; Cherif H; Carlson K; Burman J
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2024;95(2):134-141
Trajectories of cognitive processing speed and physical disability over 11 years following initiation of a first multiple sclerosis disease-modulating therapy
Longinetti E; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould AM; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Olsson T; Piehl F; Frisell T
Article: ISCIENCE. 2023;26(6):106906
Disease phenotype prediction in multiple sclerosis
Herman S; McShane SA; Zjukovskaja C; Khoonsari PE; Svenningsson A; Burman J; Spjuth O; Kultima K
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2023;70:104481
Predictors of patient-reported fatigue symptom severity in a nationwide multiple sclerosis cohort
Englund S; Kierkegaard M; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Olsson T; Longinetti E; Frisell T; Piehl F
Article: FRONTIERS IN IMMUNOLOGY. 2023;14:1241199
Validation of elevated levels of interleukin-8 in the cerebrospinal fluid, and discovery of new biomarkers in patients with GBS and CIDP using a proximity extension assay
Kmezic I; Gustafsson R; Fink K; Svenningsson A; Samuelsson K; Ingre C; Olsson T; Hansson M; Kockum I; Adzemovic MZ; Press R
Article: BRAIN COMMUNICATIONS. 2022;5(1):fcad011
Cerebrospinal fluid cytokines after autologous haematopoietic stem cell transplantation and intrathecal rituximab treatment for multiple sclerosis
Burman J; Zjukovskaja C; Svenningsson A; Freyhult E; Wiberg A; Kultima K
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2022;68:104220
Effectiveness of first generation disease-modifying therapy to prevent conversion to secondary progressive multiple sclerosis
Tedeholm H; Piehl F; Lycke J; Link J; Stawiarz L; Burman J; de Flon P; Fink K; Gunnarsson M; Mellergard J; Nilsson P; Sundstrom P; Svenningsson A; Johansson H; Andersen O
Article: BMJ CASE REPORTS. 2022;15(9):e249156
Cerebral microvascular injuries in severe COVID-19 infection: progression of white matter hyperintensities post-infection
Petersson I; Hansen BM; Svenningsson A; Lundstrom A
Article: ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY. 2022;9(9):1449-1458
COVID-19 clinical outcomes and DMT of MS patients and population-based controls
Longinetti E; Bower H; McKay KA; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Olsson T; Piehl F; Frisell T
Article: LANCET NEUROLOGY. 2022;21(8):693-703
Safety and efficacy of rituximab versus dimethyl fumarate in patients with relapsing-remitting multiple sclerosis or clinically isolated syndrome in Sweden: a rater-blinded, phase 3, randomised controlled trial
Svenningsson A; Frisell T; Burman J; Salzer J; Fink K; Hallberg S; Hambraeus J; Axelsson M; Al Nimer F; Sundstrom P; Gunnarsson M; Johansson R; Mellergard J; Rosenstein I; Ayad A; Sjoblom I; Risedal A; de Flon P; Gilland E; Lindeberg J; Shawket F; Piehl F; Lycke J
Article: JAMA NEUROLOGY. 2021;78(10):1197-1204
Treatment Escalation vs Immediate Initiation of Highly Effective Treatment for Patients With Relapsing-Remitting Multiple Sclerosis Data From 2 Different National Strategies
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
Article: METABOLITES. 2021;11(2):126
Metabolomics of Cerebrospinal Fluid from Healthy Subjects Reveal Metabolites Associated with Ageing
Carlsson H; Rollborn N; Herman S; Freyhult E; Svenningsson A; Burman J; Kultima K
Article: JOURNAL OF NEUROLOGY. 2021;268(2):651-657
Intrathecal treatment trial of rituximab in progressive MS: results after a 2-year extension
Bergman J; Burman J; Bergenheim T; Svenningsson A
Article: MULTIPLE SCLEROSIS AND RELATED DISORDERS. 2020;46:102463
NFL and CXCL13 may reveal disease activity in clinically and radiologically stable MS
Novakova L; Axelsson M; Malmestrom C; Zetterberg H; Blennow K; Svenningsson A; Lycke J
Article: MULTIPLE SCLEROSIS JOURNAL. 2020;26(12):1532-1539
Comparative effectiveness of dimethyl fumarate as the initial and secondary treatment for MS
Granqvist M; Burman J; Gunnarsson M; Lycke J; Nilsson P; Olsson T; Sundstrom P; Svenningsson A; Vrethem M; Frisell T; Piehl F
Article: FLUIDS AND BARRIERS OF THE CNS. 2020;17(1):49
Location matters: highly divergent protein levels in samples from different CNS compartments in a clinical trial of rituximab for progressive MS
Bergman J; Svenningsson A; Liv P; Bergenheim T; Burman J
Article: ANNALS OF NEUROLOGY. 2020;87(5):688-699
Cancer Risk for Fingolimod, Natalizumab, and Rituximab in Multiple Sclerosis Patients
Alping P; Askling J; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2020;27(5):871-877
Prevention of post-dural puncture headache: a randomized controlled trial
Salzer J; Granasen G; Sundstrom P; Vagberg M; Svenningsson A
Article: LANCET NEUROLOGY. 2020;19(4):307-316
Timing of high-efficacy therapy for multiple sclerosis: a retrospective observational cohort study
He A; Merkel B; Brown JWL; Ryerson LZ; Kister I; Malpas CB; Sharmin S; Horakova D; Havrdova EK; Spelman T; Izquierdo G; Eichau S; Trojano M; Lugaresi A; Hupperts R; Sola P; Ferraro D; Lycke J; Grand'Maison F; Prat A; Girard M; Duquette P; Larochelle C; Svenningsson A; Petersen T; Grammond P; Granella F; Van Pesch V; Bergamaschi R; McGuigan C; Coles A; Hillert J; Piehl F; Butzkueven H; Kalincik T
Article: METABOLOMICS. 2020;16(2):26
Targeted metabolomics of CSF in healthy individuals and patients with secondary progressive multiple sclerosis using high-resolution mass spectrometry
Carlsson H; Abujrais S; Herman S; Khoonsari PE; Akerfeldt T; Svenningsson A; Burman J; Kultima K
Article: JAMA NEUROLOGY. 2020;77(2):184-191
Infection Risks Among Patients With Multiple Sclerosis Treated With Fingolimod, Natalizumab, Rituximab, and Injectable Therapies
Luna G; Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Article: PAIN. 2019;160(11):2603-2611
Cerebrospinal fluid biomarkers of inflammation in trigeminal neuralgia patients operated with microvascular decompression
Ericson H; Abu Hamdeh S; Freyhult E; Stiger F; Backryd E; Svenningsson A; Gordh T; Kultima K
Article: JOURNAL OF NEUROLOGY. 2019;266(9):2208-2215
Lower risk of multiple sclerosis in patients with chronic hepatitis C: a nationwide population-based registry study
Soderholm J; Yilmaz A; Svenningsson A; Busch K; Wejstal R; Brolund A; Kovamees J; Sallberg M; Lagging M; Gisslen M
Article: EUROPEAN JOURNAL OF NEUROLOGY. 2019;26(8):1060-1067
Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis
Boremalm M; Juto A; Axelsson M; Novakova L; Frisell T; Svenningsson A; Lycke J; Piehl F; Selzer J
Article: JOURNAL OF NEUROIMMUNOLOGY. 2019;332:31-36
Measurement of sCD27 in the cerebrospinal fluid identifies patients with neuroinflammatory disease
Feresiadou A; Nilsson K; Ingelsson M; Press R; Kmezic I; Nygren I; Svenningsson A; Niemela V; Gordh T; Cunningham J; Kultima K; Larsson A; Burman J
Article: ACTA NEUROLOGICA SCANDINAVICA. 2019;139(5):462-468
Comparison of plasma and cerebrospinal fluid neurofilament light in a multiple sclerosis trial
de Flon P; Laurell K; Sundstrom P; Blennow K; Soderstrom L; Zetterberg H; Gunnarsson M; Svenningsson A
Article: EPIDEMIOLOGY. 2019;30(2):230-233
Validation of the Swedish Multiple Sclerosis Register Further Improving a Resource for Pharmacoepidemiologic Evaluations
Alping P; Piehl F; Langer-Gould A; Frisell T; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Kockum I; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Virtanen S; Vrethem M
Article: MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL. 2019;5(1):2055217319826598
Inflammatory activity and vitamin D levels in an MS population treated with rituximab
Linden J; Granasen G; Salzer J; Svenningsson A; Sundstrom P
Article: NEUROLOGY. 2018;91(20):e1893-e1901
Intrathecal treatment trial of rituximab in progressive MS An open-label phase 1b study
Bergman J; Burman J; Gilthorpe JD; Zetterberg H; Jiltsova E; Bergenheim T; Svenningsson A
Article: JAMA NEUROLOGY. 2018;75(3):320-327
Comparative Effectiveness of Rituximab and Other Initial Treatment Choices for Multiple Sclerosis
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
Article: PLOS ONE. 2018;13(2):e0192516
Immunological profile in cerebrospinal fluid of patients with multiple sclerosis after treatment switch to rituximab and compared with healthy controls
de Flon P; Soderstrom L; Laurell K; Dring A; Sundstrom P; Gunnarsson M; Svenningsson A
Article: NEUROLOGY. 2017;89(22):2230-2237
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Novakova L; Zetterberg H; Sundstrom P; Axelsson M; Khademi M; Gunnarsson M; Malmestrom C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Article: MULTIPLE SCLEROSIS JOURNAL. 2017;23(9):1249-1257
Improved treatment satisfaction after switching therapy to rituximab in relapsing-remitting MS
de Flon P; Laurell K; Soderstrom L; Gunnarsson M; Svenningsson A
Article: JOURNAL OF NEURORADIOLOGY. 2016;43(6):384-391
Brain parenchymal fraction in an age-stratified healthy population - determined by MRI using manual segmentation and three automated segmentation methods
Vagberg M; Ambarki K; Lindqvist T; Birgander R; Svenningsson A
Article: IDEGGYOGYASZATI SZEMLE. 2016;69(11-12):397-402
HOW TO MINIMIZE THE RISK FOR HEADACHE? A LUMBAR PUNCTURE PRACTICE QUESTIONNAIRE STUDY
Salzer J; Rajda C; Sundstrom P; Vagberg M; Vecsei L; Svenningsson A
Article: NEUROLOGY. 2016;87(20):2074-2081
Rituximab in multiple sclerosis A retrospective observational study on safety and efficacy
Salzer J; Svenningsson R; Alping P; Novakova L; Bjorck A; Fink K; Islam-Jakobsson P; Malmestrm C; Axelsson M; Vagberg M; Sundstrom P; Lycke J; Piehl F; Svenningsson A
Article: NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2016;3(5):e271
Neurofilament light in CSF and serum is a sensitive marker for axonal white matter injury in MS
Bergman J; Dring A; Zetterberg H; Blennow K; Norgren N; Gilthorpe J; Bergenheim T; Svenningsson A
Article: NEUROLOGY. 2016;87(2):141-147
Reduced inflammation in relapsing-remitting multiple sclerosis after therapy switch to rituximab
de Flon P; Gunnarsson M; Laurell K; Soderstrom L; Birgander R; Lindqvist T; Krauss W; Dring A; Bergman J; Sundstrom P; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2016;22(8):1027-1031
Vitamin D and axonal injury in multiple sclerosis
Sandberg L; Bistrom M; Salzer J; Vagberg M; Svenningsson A; Sundstrom P
Article: ANNALS OF NEUROLOGY. 2016;79(6):950-958
Rituximab versus Fingolimod after Natalizumab in Multiple Sclerosis Patients
Alping P; Frisell T; Novakova L; Islam-Jakobsson P; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Lycke J; Svenningsson A; Piehl F
Article: JOURNAL OF NEUROIMMUNOLOGY. 2016;292:40-44
Cerebrospinal fluid concentration of Galectin-9 is increased in secondary progressive multiple sclerosis
Burman J; Svenningsson A
Article: JOURNAL OF NEUROLOGY. 2016;263(2):322-326
Rituximab in paediatric onset multiple sclerosis: a case series
Salzer J; Lycke J; Wickstrom R; Naver H; Piehl F; Svenningsson A
Article: NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2016;3(1):e191
Lipocalin-2 is increased in progressive multiple sclerosis and inhibits remyelination
Al Nimer F; Elliott C; Bergman J; Khademi M; Dring AM; Aeinehband S; Bergenheim T; Christensen JR; Sellebjerg F; Svenningsson A; Linington C; Olsson T; Piehl F
Article: ACTA NEUROLOGICA SCANDINAVICA. 2015;132(6):389-394
Increasing prevalence of multiple sclerosis in Vasterbotten County of Sweden
Svenningsson A; Salzer J; Vagberg M; Sundstrom P; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL - EXPERIMENTAL, TRANSLATIONAL AND CLINICAL. 2015;1:2055217315608203
Improved working ability in a contemporary MS population compared with a historic non-treated MS population in the same geographic area of Sweden.
Wickström A; Sundström P; Wickström L; Dahle C; Vrethem M; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2015;21(8):1036-1044
Natalizumab exerts a suppressive effect on surrogates of B cell function in blood and CSF
Warnke C; Stettner M; Lehmensiek V; Dehmel T; Mausberg AK; von Geldern G; Gold R; Kuempfel T; Hohlfeld R; Maeurer M; Stangel M; Straeten V; Limmroth V; Weber T; Kleinschnitz C; Wattjes MP; Svenningsson A; Olsson T; Hartung H-P; Hermsen D; Tumani H; Adams O; Kieseier BC
Article: NEUROLOGY: NEUROIMMUNOLOGY & NEUROINFLAMMATION. 2015;2(2):e79
Rapid depletion of B lymphocytes by ultra-low-dose rituximab delivered intrathecally.
Svenningsson A; Bergman J; Dring A; Vågberg M; Birgander R; Lindqvist T; Gilthorpe J; Bergenheim T
Article: PLOS ONE. 2015;10(7):e0132177
Comparative Assessment of the Prognostic Value of Biomarkers in Traumatic Brain Injury Reveals an Independent Role for Serum Levels of Neurofilament Light
Al Nimer F; Thelin E; Nystrom H; Dring AM; Svenningsson A; Piehl F; Nelson DW; Bellander B-M
Article: NEUROLOGICAL RESEARCH. 2015;37(1):92-94
Lumbar puncture preferences among Swedish neurologists
Salzer J; Sundstroem P; Vagberg M; Svenningsson A
Article: PLOS ONE. 2015;10(8):e0135886
Levels and Age Dependency of Neurofilament Light and Glial Fibrillary Acidic Protein in Healthy Individuals and Their Relation to the Brain Parenchymal Fraction
Vagberg M; Norgren N; Dring A; Lindqvist T; Birgander R; Zetterberg H; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2015;21(1):48-56
Age-dependent effects on the treatment response of natalizumab in MS patients
Matell H; Lycke J; Svenningsson A; Holmen C; Khademi M; Hillert J; Olsson T; Piehl F
Article: FRONTIERS IN NEUROLOGY. 2015;6:18
Improvement in fatigue during natalizumab treatment is linked to improvement in depression and day-time sleepiness
Penner I-K; Sivertsdotter EC; Celius EG; Fuchs S; Schreiber K; Berko S; Svenningsson A
Article: JOURNAL OF NEUROIMMUNOLOGY. 2014;277(1-2):153-159
The cerebrospinal fluid cytokine signature of multiple sclerosis: A homogenous response that does not conform to the Th1/Th2/Th17 convention
Burman J; Svensson E; Fransson M; Loskog ASI; Zetterberg H; Raininko R; Svenningsson A; Fagius J; Mangsbo SM
Article: ANNALS OF NEUROLOGY. 2014;76(6):792-801
Cerebrospinal Fluid JC Virus Antibody Index for Diagnosis of Natalizumab-Associated Progressive Multifocal Leukoencephalopathy
Warnke C; von Geldern G; Markwerth P; Dehmel T; Hoepner R; Gold R; Pawlita M; Kuempfel T; Maeurer M; Stangel M; Wegner F; Hohlfeld R; Straeten V; Limmroth V; Weber T; Hermsen D; Kleinschnitz C; Hartung H-P; Wattjes MP; Svenningson A; Major E; Olsson T; Kieseier BC; Adams O
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2014;85(10):1116-1121
Autologous haematopoietic stem cell transplantation for aggressive multiple sclerosis: the Swedish experience
Burman J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson J-E; Isaksson C; Hagglund H; Carlson K; Fagius J
Article: MULTIPLE SCLEROSIS JOURNAL. 2014;20(8):1095-1101
Reduced sick leave in multiple sclerosis after one year of natalizumab treatment. A prospective ad hoc analysis of the TYNERGY trial
Wickstrom A; Dahle C; Vrethem M; Svenningsson A
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2014;85(6):618-624
Autologous haematopoietic stem cell transplantation: a viable treatment option for CIDP
Press R; Askmark H; Svenningsson A; Andersen O; Axelson HW; Stroemberg U; Wahlin A; Isaksson C; Johansson J-EJ; Haegglund H
Article: MULTIPLE SCLEROSIS JOURNAL. 2014;20(1):43-50
Immunosuppressive therapy reduces axonal damage in progressive multiple sclerosis
Axelsson M; Malmestrom C; Gunnarsson M; Zetterberg H; Sundstrom P; Lycke J; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2013;19(5):622-630
Improved ability to work after one year of natalizumab treatment in multiple sclerosis. Analysis of disease-specific and work-related factors that influence the effect of treatment
Wickstrom A; Nystrom J; Svenningsson A
Article: AMERICAN JOURNAL OF NEURORADIOLOGY. 2013;34(3):498-504
Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis
Vagberg M; Lindqvist T; Ambarki K; Warntjes JBM; Sundstrom P; Birgander R; Svenningsson A
Journal article: EUROPEAN NEUROLOGICAL REVIEW. 2013;8((Suppl.1)):10
Clinical, Biochemical and Imaging Parameters that may be Predictive of High Disease Activity, Rapid Progression or Increased Disability in Multiple Sclerosis
Svenningsson A; Hendin BA
Article: PLOS ONE. 2013;8(3):e58643
Natalizumab Treatment Reduces Fatigue in Multiple Sclerosis. Results from the TYNERGY Trial; A Study in the Real Life Setting
Svenningsson A; Falk E; Celius EG; Fuchs S; Schreiber K; Berko S; Sun J; Penner I-K
Article: PLOS ONE. 2013;8(5):e63172
Intense Inflammation and Nerve Damage in Early Multiple Sclerosis Subsides at Older Age: A Reflection by Cerebrospinal Fluid Biomarkers
Khademi M; Dring AM; Gilthorpe JD; Wuolikainen A; Al Nimer F; Harris RA; Andersson M; Brundin L; Piehl F; Olsson T; Svenningsson A
Article: NEUROLOGICAL RESEARCH. 2012;34(7):730-733
Humoral immune response to influenza vaccine in natalizumab-treated MS patients
Vagberg M; Kumlin U; Svenningsson A
Journal article: NEUROLOGY. 2012;78(Meeting Abstracts 1):p07.081
Natalizumab Reduces Fatigue as Measured by the Fatigue Scale for Motor and Cognitive Functions (FSMC) - First Results from the TYNERGY Trial (P07.081)
Svenningsson A; Celius E; Schreiber K; Fuchs S; Falk E; Berko S; Max Moller C; Penner IK
Journal article: NEUROLOGY. 2012;78(Meeting Abstracts 1):p03.055
Automated Determination of Brain Parenchymal Fraction in Multiple Sclerosis (P03.055)
Vagberg M; Lindqvist T; Warntjes M; Sundstrom P; Birgander R; Svenningsson A
Article: BIODRUGS. 2011;25(5):299-306
Effect of Treatment with Natalizumab on Ability to Work in People with Multiple Sclerosis Productivity Gain Based on Direct Measurement of Work Capacity before and after 1 Year of Treatment
Olofsson S; Wickstrom A; Glenngard AH; Persson U; Svenningsson A
Article: MULTIPLE SCLEROSIS JOURNAL. 2011;17(6):708-719
A Swedish national post-marketing surveillance study of natalizumab treatment in multiple sclerosis
Holmen C; Piehl F; Hillert J; Fogdell-Hahn A; Lundkvist M; Karlberg E; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Olsson T
Article: ANNALS OF NEUROLOGY. 2011;69(1):83-89
Axonal Damage in Relapsing Multiple Sclerosis is Markedly Reduced by Natalizumab
Gunnarsson M; Malmestrom C; Axelsson M; Sundstrom P; Dahle C; Vrethem M; Olsson T; Piehl F; Norgren N; Rosengren L; Svenningsson A; Lycke J
Article: CLINICAL NEUROPHARMACOLOGY. 2010;33(5):260-264
Efficacy and Safety of the Dopaminergic Stabilizer Pridopidine (ACR16) in Patients With Huntington's Disease
Lundin A; Dietrichs E; Haghighi S; Goller M-L; Heiberg A; Loutfi G; Widner H; Wiktorin K; Wiklund L; Svenningsson A; Sonesson C; Waters N; Waters S; Tedroff J
Article: MULTIPLE SCLEROSIS JOURNAL. 2010;16(3):287-292
Neurofilament light as a prognostic marker in multiple sclerosis
Salzer J; Svenningsson A; Sundstrom P
Article: ACTA NEUROLOGICA SCANDINAVICA. 2010;121(1):20-23
Season of birth and multiple sclerosis in Sweden
Salzer J; Svenningsson A; Sundstrom P
Article: LANCET NEUROLOGY. 2009;8(6):519-529
NORdic trial of oral Methylprednisolone as add-on therapy to Interferon beta-1a for treatment of relapsing-remitting Multiple Sclerosis (NORMIMS study): a randomised, placebo-controlled trial
Sorensen PS; Mellgren SI; Svenningsson A; Elovaara I; Frederiksen JL; Beiske AG; Myhr K-M; Sogaard LV; Olsen IC; Wollheim MS
Article: NEUROLOGY. 2004;63(9):1586-1590
Neurofilament and glial fibrillary acidic protein in multiple sclerosis
Norgren N; Sundström P; Svenningsson A; Rosengren L; Stigbrand T; Gunnarsson M
Article: NEUROLOGY. 2004;62(12):2277-2282
An altered immune response to Epstein-Barr virus in multiple sclerosis -: A prospective study
Sundström P; Juto P; Wadell G; Hallmans G; Svenningsson A; Nyström L; Dillner J; Forsgren L
Article: JOURNAL OF NEUROLOGY, NEUROSURGERY AND PSYCHIATRY. 2004;75(5):711-716
Clinical characteristics of multiple sclerosis in Vasterbotten County in northern Sweden
Sundström P; Svenningsson A; Nyström L; Forsgren L
Article: MULTIPLE SCLEROSIS JOURNAL. 2003;9(5):515-520
Sick leave and professional assistance for multiple sclerosis individuals in Vasterbotten County, northern Sweden
Sundström P; Nyström L; Svenningsson A; Forsgren L
Article: ANNALS OF NEUROLOGY. 2002;51(4):467-474
Antibody-mediated suppression of Vβ5.2/5.3⁺ T cells in multiple sclerosis:: Results from an MRI-monitored phase II clinical trial
Killestein J; Olsson T; Wallström E; Svenningsson A; Khademi M; Blumhardt LD; Fagius J; Hillert J; Landtblom AM; Edenius C; Årfors L; Barkhof F; Polman CH
Article: SCANDINAVIAN JOURNAL OF IMMUNOLOGY. 2002;55(3):264-273
Differential expression of neurotrophic factors and inflammatory cytokines by myelin basic protein-specific and other recruited T cells infiltrating the central nervous system during experimental autoimmune encephalomyelitis
Muhallab S; Lundberg C; Gielen AW; Lidman O; Svenningsson A; Piehl F; Olsson T
Article: JOURNAL OF NEUROIMMUNOLOGY. 2001;113(2):202-211
Intra-CNS activation by antigen-specific T lymphocytes in experimental autoimmune encephalomyelitis
Muhallab S; Lidman O; Weissert R; Olsson T; Svenningsson A
Article: JOURNAL OF NEUROSCIENCE. 2000;20(14):5283-5291
Neuroprotection by encephalomyelitis:: Rescue of mechanically injured neurons and neurotrophin production by CNS-infiltrating T and natural killer cells
Hammarberg H; Lidman O; Lundberg C; Eltayeb SY; Gielen AW; Muhallab S; Svenningsson A; Lindå H; van der Meide PH; Cullheim S; Olsson T; Piehl F
Article: NEUROLOGY. 1999;53(8):1880-1882
Nitric oxide metabolites in CSF of patients with MS are related to clinical disease course
Svenningsson A; Petersson AS; Andersen O; Hansson GK
Article: JOURNAL OF IMMUNOLOGY. 1998;160(2):681-690
Molecular and genetic requirements for preferential recruitment of TCRBV8S2⁺ T cells in Lewis rat experimental autoimmune encephalomyelitis
Weissert R; Svenningsson A; Lobell A; de Graaf KL; Andersson R; Olsson T
Journal article: CYTOMETRY. 1997;29(2):155-164
Identification and analysis of macrophage‐derived foam cells from human atherosclerotic lesions by using a “mock” FL3 channel in flow cytometry
Liu‐Wu Y; Svenningsson A; Stemme S; Holm J; Wiklund O
Article: CYTOMETRY. 1997;29(2):155-164
Identification and analysis of macrophage-derived foam cells from human atherosclerotic lesions by using a ''mock'' FL3 channel in flow cytometry
LiuWu Y; Svenningsson A; Stemme S; Holm J; Wiklund O
Article: JOURNAL OF NEUROIMMUNOLOGY. 1997;75(1-2):59-68
Increased expression of B7-1 costimulatory molecule on cerebrospinal fluid cells of patients with multiple sclerosis and infectious central nervous system disease
Svenningsson A; Dotevall L; Stemme S; Andersen O
Article: NEUROLOGY. 1996;47(4):895-900
Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Astrom M; Gjorstrup P; Ekholm S
Article: MULTIPLE SCLEROSIS JOURNAL. 1996;1(6):348
Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis.
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde AS; Aström M; Gjörstrup P; Ekholm S
Article: JOURNAL OF NEUROIMMUNOLOGY. 1995;63(1):39-46
Lymphocyte phenotype and subset distribution in normal cerebrospinal fluid
Svenningsson A; Andersen O; Edsbagge M; Stemme S
Article: JOURNAL OF LIPID RESEARCH. 1995;36(11):2282-2290
DIFFERENTIAL REGULATION OF MACROPHAGE SCAVENGER RECEPTOR ISOFORMS - MESSENGER-RNA QUANTIFICATION USING THE POLYMERASE CHAIN-REACTION
DUFVA M; SVENNINGSSON A; HANSSON GK
Journal article: JOURNAL OF NEUROIMMUNOLOGY. 1995;56:26
Linomide reduces the rate of active lesions in relapsing-remitting multiple sclerosis
Andersen O; Lycke J; Tollesson PO; Svenningsson A; Runmarker B; Linde A; Aström M; Gjörstrup P; Ekholm S
Article: AUTOIMMUNITY. 1995;21(4):231-239
Reduced frequency of memory CD8(+) T lymphocytes in cerebrospinal fluid and blood of patients with multiple sclerosis
Svenningsson A; Andersen O; Hansson GK; Stemme S
Journal article: CNS DRUGS. 1994;2(2):87-95
Cell Adhesion Molecules in Multiple Sclerosis
Svenningsson A; Stemme S
Journal article: JOURNAL OF NEUROLOGY. 1994;241(4):204-209
Human spumaretrovirus antibody reactivity in multiple sclerosis.
Lycke J; Svennerholm B; Svenningsson A; Muranyi W; Flügel RM; Andersen O
Journal article: ACTA NEUROLOGICA SCANDINAVICA. 1993;88(3):199-203
POSSIBLE ASSOCIATION OF HTLV-I INFECTION AND DEMENTIA
LYCKE J; SVENNERHOLM B; SVENNINGSSON A; HORAL P; NORDQVISTBRANDT E; ANDERSEN O
Journal article: ANNALS OF NEUROLOGY. 1993;34(2):155-161
ADHESION MOLECULE EXPRESSION ON CEREBROSPINAL-FLUID T-LYMPHOCYTES - EVIDENCE FOR COMMON RECRUITMENT MECHANISMS IN MULTIPLE-SCLEROSIS, ASEPTIC-MENINGITIS, AND NORMAL CONTROLS
SVENNINGSSON A; HANSSON GK; ANDERSEN O; ANDERSSON R; PATARROYO M; STEMME S
Journal article: ANNALS OF NEUROLOGY. 1992;32(5):711-714
No evidence for spumavirus or oncovirus infection in relapsing-remitting multiple sclerosis.
Svenningsson A; Lycke J; Svennerholm B; Gronowitz S; Andersen O
Journal article: LAKARTIDNINGEN. 1992;89(43):3590
[Conventional methods lead to faulty diagnosis of obscure proteinuria].
Grubb A; Svenningsson A; Westberg G
Journal article: AIDS. 1992;6(9):915-923
HIV-1 IN POSTMORTEM BRAIN-TISSUE FROM PATIENTS WITH AIDS - A COMPARISON OF DIFFERENT DETECTION TECHNIQUES
SHAPSHAK P; YOSHIOKA M; SUN NCJ; NELSON SJ; RHODES RH; SCHILLER P; RESNICK L; SHAH SM; SVENNINGSSON A; IMAGAWA DT
Journal article: ACTA NEUROPATHOLOGICA. 1992;84(3):297-306
SIMULTANEOUS DETECTION OF FERRITIN AND HIV-1 IN REACTIVE MICROGLIA
YOSHIOKA M; SHAPSHAK P; SUN NCJ; NELSON SJ; SVENNINGSSON A; TATE LG; PARDO V; RESNICK L
Journal article: AIDS. 1991;5(6):769
HIV-1 INFECTION OF CD4-NEGATIVE CELLS VIA HTLV PSEUDOVIRONS
RAFFANTI A; SVENNINGSSON A; RESNICK L
Journal article: JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES. 1991;4(3):228-237
HIV-1 PROPAGATES IN HUMAN NEUROBLASTOMA-CELLS
SHAPSHAK P; SUN NCJ; RESNICK L; THORNTHWAITE JT; SCHILLER P; YOSHIOKA M; SVENNINGSSON A; TOURTELLOTTE WW; IMAGAWA DT
Journal article: NEUROLOGY. 1991;41(1):85-87
TROPICAL SPASTIC PARAPARESIS-LIKE ILLNESS OCCURRING IN A PATIENT DUALLY INFECTED WITH HIV-1 AND HTLV-II
BERGER JR; SVENNINGSSON A; RAFFANTI S; RESNICK L
Journal article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 1990;264(19):2501
DETERMINATION OF HIV-1 STATUS OF DISCARDED SHARPS - POLYMERASE CHAIN-REACTION USING MINUTE QUANTITIES OF BLOOD
RAFFANTI S; SVENNINGSSON A; RESNICK L
Journal article: JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (JAMA). 1990;264(19):2501b-2501
Determination of HIV-1 status of discarded sharps: polymerase chain reaction using minute quantities of blood
Raffanti S
Journal article: ACTA NEUROLOGICA SCANDINAVICA. 1990;82(3):161-168
INCIDENCE OF MS DURING 2 15-YEAR PERIODS IN THE GOTHENBURG REGION OF SWEDEN
SVENNINGSSON A; RUNMARKER B; LYCKE J; ANDERSEN O
Journal article: JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY. 1990;49(3):351
COMBINED IMMUNOHISTOCHEMISTRY AND IN SITU HYBRIDIZATION TO DETECT HIV IN AIDS BRAIN CELLS
SHAPSHAK P; YOSHIOKA M; SVENNINGSSON A; RESNICK L; NELSON S; TATE L
Show more

All other publications

Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:968-969
CLADCOMS- CLADribine tablets long-term Control Of MS - a post-marketing investigator driven study
Larsson V; Nilsson P; Magdalena LA; Svenningsson A; Gunnarsson M; Ayad A; Vrethem M; Burman J; Lycke J; Piehl F; Fink K
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:101
Can we reduce costs of our high efficacy MS therapies?
Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:616
Clinical Effectiveness and Safety of Cladribine Tablets for Patients Treated at least 24 Months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 10"(IMSE 10)
Larsson V; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:617
A comparison of administration and discontinuation of Natalizuamb in Sweden over time for patients treated with either sucutaneous (SC) or intravenous (IV) administration methods since July 2021
Forsberg L; Larsson V; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:965-966
Improved clinical outcomes in patients treated with Natalizumab for at least 11 years - Real-world data from a Swedish national post-marketing surveillance study (IMSE 1)
Forsberg L; Larsson V; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:358-359
Hypogammaglobulinemia during rituximab treatment in multiple sclerosis - the Hypogamma-MS study
Hallberg S; Evertsson B; Lillvall E; Boremalm M; de Flon P; Salzer J; Lycke J; Fink K; Wang Y; Frisell T; Al Nimer F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2023;29:617-618
Prediction of gammaglobulin decrease during rituximab treatment in MS
Kallin S; Hallberg S; Evertsson B; Wang Y; Fink K; Salzer J; Lycke J; Al Nimer F; Svenningsson A
Editorial comment: MULTIPLE SCLEROSIS JOURNAL. 2022;28(8):1177-1178
Long-term treatment with anti-CD20 monoclonal antibodies is untenable because of risk: Commentary
Lycke J; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):515-516
SARS-COV2 exposure rates and serological response of people living with MS
Longinetti E; Hogelin KA; Kockum I; Englund S; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Nilsson P; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Mellergard J; Frisell T; Olsson T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):858-859
Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 6 years in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 5" (IMSE 5)
Forsberg L; Ekstrom E; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Lantblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):352-353
Improved clinical outcomes in patients treated with natalizumab for at least 11 years - real-world data from a swedish national post-marketing surveillance study (IMSE 1)
Forsberg L; Ekstrom E; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2022;28(3_SUPPL):638-639
Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the Swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)
Rosengren V; Forsberg L; Ekstrom E; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Editorial comment: NEUROLOGY. 2021;96(23):1067-1068
Perinatal Depression and Anxiety in Multiple Sclerosis Treatable Distress
Leavitt VM; Dobson R; Svennigsson A
Preprint: SSRN ELECTRONIC JOURNAL. 2021
The Effect of Different National Treatment Strategies on Disability Outcome in Relapsing-Remitting Multiple Sclerosis: A Propensity Score Adjusted Comparison between Denmark and Sweden
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):21-22
Effectiveness of initial MS treatments in the COMBAT-MS trial: injectables, dimethyl fumarate, natalizumab and rituximab
Alping P; Burman J; Fink K; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Olsson T; Salzer J; Svenningsson A; Vrethem M; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):677-678
Trajectories of processing speed, disability, and their connections, over the years following disease modulatory treatment initiation among relapsing-remitting multiple sclerosis patients
Longinetti E; Englund S; Burman J; Fogdell-Hahn A; Gunnarsson M; Hillert J; Langer-Gould A; Lycke J; Nilsson P; Salzer J; Svenningsson A; Vrethem M; Olsson T; Piehl F; Frisell T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):671-672
The effect of different national treatment strategies on disability outcome in relapsing-remitting multiple sclerosis: a propensity score adjusted comparison between Denmark and Sweden
Spelman T; Magyari M; Piehl F; Svenningsson A; Rasmussen PV; Kant M; Sellebjerg F; Joensen H; Hillert J; Lycke J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):615-616
Clinical effectiveness and safety of dimethyl fumarate for patients treated at least 5 years in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 5" (IMSE 5)
Rosengren V; Ekstrom E; Forsberg L; Kagstrom S; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):618-619
The long-term safety and effectiveness of natalizumab (IMSE 1) - Real-world data from a Swedish nationwide pharmaco-epidemiological study
Ekstrom E; Rosengren V; Kagstrom S; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):623-624
Clinical effectiveness and safety of cladribine tablets for patients treated at least 12 months in the swedish post-market surveillance study "immunomodulation and multiple sclerosis epidemiology 10" (IMSE 10)
Rosengren V; Ekstrom E; Forsberg L; Kagstrom S; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):616-617
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)
Ekstrom E; Rosengren V; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):626-627
Real-world longitudinal data of peginterferon beta-1a from the Swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile
Ekstrom E; Rosengren V; Kagstrom S; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2021;27(2_SUPPL):612-613
Clinical effectiveness and safety of teriflunomide for patients treated at least 48 months in the Swedish post-market surveillance study "Immunomodulation and Multiple Sclerosis Epidemiology 4" (IMSE 4)
Rosengren V; Ekstrom E; Forsberg L; Kagstrom S; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2020;27:14-15
Prevention of post-dural puncture headache - a randomized controlled trial
Salzer J; Granasen G; Sundstrom P; Vagberg M; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):279-280
Efficacy and safety in patients treated with natalizumab for at least 10 years - real-world data from a swedish national surveillance study (IMSE 1)
Kagstrom S; Leandersson A; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Sundstrom P; Martin C; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):252-253
A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (imse 3) for patients treated for at least 36 months
Leandersson A; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):187-188
Relation of edss to patient-reported outcome measurements in ms: real-world data from a swedish nationwide study of fingolimod (imse 2)
Leandersson A; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):302
Real-world data of peginterferon beta-1a from a swedish national post-marketing surveillance study (IMSE 6) - effectiveness and safety profile
Kagstrom S; Leandersson A; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):254-255
A swedish post-market surveillance study: long-term effectiveness and safety of dimethyl fumarate (imse 5) for patients treated at least 36 months: on-demand eposters p0001-p0286
Forsberg L; Kagstrom S; Leandersson A; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):253-254
A swedish post-market surveillance study of the long-term effectiveness and safety of teriflunomid (IMSE 4) for patients treated at least 36 months
Forsberg L; Kagstrom S; Leandersson A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2020;26(3_SUPPL):254
A swedish post-market surveillance study: long-term effectiveness and safety of cladribine tablets (IMSE 10) for patients treated at least 12 months
Forsberg L; Kagstrom S; Leandersson A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Letter: PAIN. 2019;160(12):2898-2899
Anti-inflammatory drugs with more penetration into the central nervous system may contribute to the treatment of trigeminal neuralgia Reply
Ericson H; Abu Hamdeh S; Freyhult E; Stiger F; Backryd E; Svenningsson A; Gordh T; Kultima K
Other: NEUROLOGY: CLINICAL PRACTICE. 2019;9(6):519-521
Serum sickness following rituximab therapy in multiple sclerosis
Holmoy T; Fogdell-Hahn A; Svenningsson A
Review: JAMA NEUROLOGY. 2019;76(9):1035-1048
Diagnostic Value of Cerebrospinal Fluid Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis
Bridel C; van Wieringen WN; Zetterberg H; Tijms BM; Teunissen CE; Alvarez-Cermeno JC; Andreasson U; Axelsson M; Backstrom DC; Bartos A; Bjerke M; Blennow K; Boxer A; Brundin L; Burman J; Christensen T; Fialova L; Forsgren L; Frederiksen JL; Gisslen M; Gray E; Gunnarsson M; Hall S; Hansson O; Herbert MK; Jakobsson J; Jessen-Krut J; Janelidze S; Johannsson G; Jonsson M; Kappos L; Khademi M; Khalil M; Kuhle J; Landen M; Leinonen V; Logroscino G; Lu C-H; Lycke J; Magdalinou NK; Malaspina A; Mattsson N; Meeter LH; Mehta SR; Modvig S; Olsson T; Paterson RW; Perez-Santiago J; Piehl F; Pijnenburg YAL; Pyykko OT; Ragnarsson O; Rojas JC; Christensen JR; Sandberg L; Scherling CS; Schott JM; Sellebjerg FT; Simone IL; Skillback T; Stilund M; Sundstrom P; Svenningsson A; Tortelli R; Tortorella C; Trentini A; Troiano M; Turner MR; van Swieten JC; Vagberg M; Verbeek MM; Villar LM; Visser PJ; Wallin A; Weiss A; Wikkelso C; Wild EJ
Other: LAKARTIDNINGEN. 2019;116:FL4F
[Diagnostic challenge in a man with intractable hiccups and vomiting: a case of neuromyelitis optica spectrum disorder (NMOSD)].
Kaloudi D; Svenningsson A; von Heijne A
Editorial comment: NEUROLOGY. 2019;92(7):313-314
Serum neurofilament light and prediction of multiple sclerosis in clinically isolated syndrome
Zetterberg H; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:282
NFL and CXCL13 reveal disease activity in clinically and radiologically stable MS
Nyren LN; Axelsson M; Malmestrom C; Svenningsson A; Zetterberg H; Blennow K; Lycke J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:20
Risk of hypogammaglobulinemia in long-term treatment with rituximab in multiple sclerosis
Hallberg S; Boremalm M; Evertsson B; Lillvall E; Johansson F; Lycke J; Piehl F; Salzer J; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:432-433
Poor correlation between protein levels in different CNS compartments in patients with progressive MS
Bergman J; Svenningsson A; Liv P; Burman J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:327-328
A swedish post-market surveillance study of the long-term effectiveness and safety of alemtuzumab (IMSE 3) for patients treated at least 24 months
Falt A; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:763-764
Improved clinical outcomes in patients treated with natalizumab for at least 8 years - real-world data from a Swedish national post-marketing surveillance study (IMSE 1)
Kagstrom S; Falt A; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Sundstrom P; Martin C; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:316
A Swedish Nationwide study of the long-term effectiveness and safety of teriflunomid based on data from the Swedish "Immunomodulation and Multiple Sclerosis Epidemiology" Study (IMSE 4)
Forsberg L; Kagstrom S; Falt A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:316-317
Clinical effectiveness of dimethyl fumarate with focus on patients treated at least 36 months - a Swedish nationwide study of the long-term effectiveness and safety of dimethyl fumarate (IMSE5)
Forsberg L; Kagstrom S; Falt A; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2019;25:536-537
A Swedish real word study of the long-term effectiveness and safety of fingolimod (IMSE 2) with focus on patients treated at least 48 months
Falt A; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:701-702
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of dimethyl fumarate (IMSE 5)
Demirbuker SS; Kagstrom S; Falt A; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Sundstrom P; Martin C; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:927-928
Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile
Kagstrom S; Falt A; Demirbuker SS; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:706-707
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)
Falt A; Kagstrom S; Demirbuker SS; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:922-923
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of teriflunomid (IMSE 4)
Demirbuker SS; Kagstrom S; Falt A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Sundstrom P; Martin C; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:699-700
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1)
Kagstrom S; Falt A; Demirbuker SS; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2018;24:696-697
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2)
Falt A; Kagstrom S; Demirbuker SS; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Martin C; Sundstrom P; Gunnarsson M; Piehl F; Olsson T
Editorial comment: NEUROLOGY. 2017;89(23):2308-2309
Cortico-juxtacortical and periventricular lesions and MS diagnostic criteria
Svenningsson A; Ciccarelli O
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:714
Baseline characteristics from the COMBAT-MS study: Initial analyses suggest main driver for therapy choice is geographic location
Alping P; Burman J; Fink K; Gunnarsson M; Lycke J; Nilsson P; Salzer J; Vrethem M; Langer-Gould A; Svenningsson A; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:1004
Vitamin D levels in a multiple sclerosis population treated with rituximab
Linden J; Salzer J; Svenningsson A; Sundstrom P
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:841
NFL and CXCL13 reveal disease activity in clinically and neuro-radiologically stable MS
Novakova L; Axelsson M; Malmestrom C; Svenningsson A; Zetterberg H; Blennow K; Lycke J
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:373-374
Comparative effectiveness of first line treatment strategies for multiple sclerosis
Granqvist M; Boremalm M; Poorghobad A; Svenningsson A; Salzer J; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:17-18
Monitoring treatment response in MS by serum NFL reflects treatment efficacy
Novakova L; Zetterberg H; Axelsson M; Malmestrom C; Svenningsson A; Blennow K; Lycke J
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2017;24:577
Neurofilament light in serum for monitoring multiple sclerosis: A new quantitative tool for measuring disease activity and therapeutic response
Novakova L; Zetterberg H; Axelsson M; Sundstrom P; Khademi M; Gunnarsson M; Malmestrom C; Svenningsson A; Olsson T; Piehl F; Blennow K; Lycke J
Review: PLOS ONE. 2017;12(1):e0170018
Brain Parenchymal Fraction in Healthy Adults-A Systematic Review of the Literature
Vagberg M; Granasen G; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:374-375
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of fingolimod (IMSE 2)
Leandersson A; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:888-889
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of alemtuzumab (IMSE 3)
Leandersson A; Kagstrom S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:626-627
Real-world longitudinal data of peginterferon beta-1a from a Swedish national post-marketing surveillance study (IMSE 6) - efficacy and safety profile
Kagstrom S; Leandersson A; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2017;23:365-366
A Swedish nationwide pharmaco-epidemiological study of the long-term safety and effectiveness of natalizumab (IMSE 1)
Kagstrom S; Leandersson A; Forsberg L; Berglund A; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Review: ACTA NEUROLOGICA SCANDINAVICA. 2017;135(1):17-24
Guidelines for the use of magnetic resonance imaging in diagnosing and monitoring the treatment of multiple sclerosis: recommendations of the Swedish Multiple Sclerosis Association and the Swedish Neuroradiological Society
Vagberg M; Axelsson M; Birgander R; Burman J; Cananau C; Forslin Y; Granberg T; Gunnarsson M; von Heijne A; Jonsson L; Karrenbauer VD; Larsson E-M; Lindqvist T; Lycke J; Lonn L; Mentesidou E; Muller S; Nilsson P; Piehl F; Svenningsson A; Vrethem M; Wikstrom J
Letter: ANNALS OF NEUROLOGY. 2016;80(5):791-792
Rituximab versus fingolimod after natalizumab in multiple sclerosis: Also consider progressive multifocal leukoencephalopathy risk Reply
Alping P; Frisell T; Svenningsson A; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:511
Cytokine levels in interstitial brain fluid in progressive multiple sclerosis measured via intracerebral microdialysis
Bergman J; Dring A; Wuolikainen A; Gilthorpe J; Bergenheim T; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:622
Changes of cerebrospinal fluid cytokine profile as a result of switching from first line MS-therapies to rituximab
de Flon P; Soderstrom L; Laurell K; Gunnarsson M; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:336-337
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and effectiveness of natalizumab (IMSE 1)
Johansson S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2016;22:49
Rituximab in multiple sclerosis; data from the swedish MS registry.
Alping P; Svenningsson A; Salzer J; Burman J; Dahle C; Fink K; Hillert J; Lycke J; Landtblom A-M; Martin C; Nilsson P; Walentin F; Olsson T; Frisell T; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:574
Rituximab in multiple sclerosis, a long term safety and efficacy study
Islam-Jakobsson P; Alping P; Salzer J; Bjorck A; Fink K; Frisell T; Piehl F; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:555
Superior efficacy and tolerability of rituximab as compared to fingolimod for MS patients switching from natalizumab due to positive JC virus serology
Alping P; Islam-Jakobsson P; Novakova L; Salzer J; Bjorck A; Axelsson M; Malmestrom C; Fink K; Frisell T; Lycke J; Svenningsson A; Piehl F
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:380
Rituximab in paediatric MS
Salzer J; Wickstrom R; Piehl F; Lycke J; Svenningsson A
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:285-286
A Swedish nationwide pharmaco-epidemiological and genetic study of the long-term safety and efficacy of natalizumab
Johansson S; Forsberg L; Hillert J; Nilsson P; Dahle C; Svenningsson A; Lycke J; Landtblom A-M; Burman J; Walentin F; Martin C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:286-287
A Swedish nationwide pharmaco-epidemiological and genetic study (IMSE) of the long-term safety and efficacy of dimethyl fumarate
Forsberg L; Johansson S; Nordin N; Hillert J; Svenningsson A; Lycke J; Burman J; Landtblom A-M; Walentin F; Martin C; Nilsson P; Dahle C; Piehl F; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2015;21:284-285
The IMSE 2 study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of fingolimod
Johansson S; Forsberg L; Nordin N; Hillert J; Svenningsson A; Lycke J; Burman J; Landtblom A-M; Walentin F; Martin C; Nilsson P; Dahle C; Piehl F; Olsson T
Letter: NEUROLOGY. 2014;82(22):2017-2025
Initial cognitive decline is associated with cortical thinning in early Parkinson disease
Pereira JB; Svenningsson P; Weintraub D; Bronnick K; Lebedev A; Westman E; Aarsland D
Letter: LAKARTIDNINGEN. 2014;111(40):1725
[Swedish neurologists--unusually disobedient when it comes to lumbar punctures].
Salzer J; Vågber M; Svenningsson A; Sunddström P
Conference publication: BONE MARROW TRANSPLANTATION. 2014;49:S41-S42
AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION FOR MULTIPLE SCLEROSIS: THE SWEDISH EXPERIENCE
Hagglund HG; Fagius J; Iacobaeus E; Svenningsson A; Lycke J; Gunnarsson M; Nilsson P; Vrethem M; Fredrikson S; Martin C; Sandstedt A; Uggla B; Lenhoff S; Johansson J-E; Isaksson C; Carlson K; Burman J
Editorial comment: NEUROLOGY. 2013;80(10):965-967
FATAL NEUROINFLAMMATION IN A CASE OF MULTIPLE SCLEROSIS WITH ANTI-NATALIZUMAB ANTIBODIES
Svenningsson A; Dring AM; Fogdell-Hahn A; Jones I; Engdahl E; Lundkvist M; Brannstrom T; Gilthorpe JD
Conference publication: BONE MARROW TRANSPLANTATION. 2013;48:S336
Autologous haematopoietic stem cell transplantation: a viable treatment option for chronic inflammatory demyelinating polyneuropathy
Hagglund H; Askmark H; Stromberg U; Axelsson H; Svenningsson A; Isaksson C; Wahlin A; Andersen O; Johansson J; Press R
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2013;19(11):445-446
The immunomodulation and multiple sclerosis epidemiology (IMSE II) study: a Swedish nationwide pharmaco-epidemiological and genetic study focussed on long-term safety and efficacy of fingolimod (Gilenya®)
Nordin N; Hillert J; Piehl F; Svenningsson A; Lycke J; Fagius J; Walentin F; Martin C; Nilsson P; Feltelius N; Dahle C; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2013;19(11):205
The immunomodulation and multiple sclerosis epidemiology (IMSE) study; a Swedish nationwide pharmaco-epidemiological and genetic study focussed on long-term safety and efficacy of natalizumab (Tysabri)
Jonsson L; Piehl F; Hillert J; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Fagius J; Wallentin F; Martin C; Olsson T
Book chapter: LAKARTIDNINGEN. 2012;p. 1170-1171
[Treatment of status epilepticus].
Salzer J; Svenningsson A
Conference publication: JOURNAL OF NEUROIMMUNOLOGY. 2012;253(1-2):100
Multivariate analysis of inflammatory and neuronal injury markers in cerebrospinal fluid of multiple sclerosis: Higher levels are associated with younger age
Khademi M; Dring A; Gilthorpe J; Wuolikainen A; Al Nimer F; Harris R; Andersson M; Brundin L; Piehl F; Olsson T; Svenningsson A
Conference publication: EUROPEAN JOURNAL OF NEUROLOGY. 2012;19:751
The 'Immunomodulation and Multiple Sclerosis Epidemiology' (IMSE) study: a Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri)
Holmen C; Piehl F; Hillert J; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Fagius J; Valentin F; Martin C; Olsson T
Conference publication: MULTIPLE SCLEROSIS JOURNAL. 2012;18:433-434
The "Immunomodulation and Multiple Sclerosis Epidemiology" (IMSE) study; A Swedish nationwide pharmaco-epidemiological and genetic study focused on long-term safety and efficacy of natalizumab (Tysabri)
Holmen C; Piehl F; Hillert J; Nilsson P; Dahle C; Feltelius N; Svenningsson A; Lycke J; Fagius J; Wallentin F; Martin C; Olsson T
Letter: ANNALS OF NEUROLOGY. 2011;69(6):1066-1067
The Neurofilament Light Chain is Not Stable in Vitro Reply
Gunnarsson M; Malmestrom C; Rosengren L; Lycke J; Svenningsson A
Corrigendum: ACTA NEUROLOGICA SCANDINAVICA. 2010;122(1):70-73
Season of birth and multiple sclerosis in Sweden (vol 121, pg 20, 2010)
Salzer J; Svenningsson A; Sundstrom P
Conference publication: THE FASEB JOURNAL. 2000;14(6):A1120
Analysis of CNS-infiltrating myelin specific T lymphocytes by flow cytometry
Muhallab S; Lidman O; Weissert R; Olsson T; Svenningsson A
Review: LAKARTIDNINGEN. 1998;95(49):5631-5635
[Treatment of multiple sclerosis--2. Application of a new immunological basic research is close].
Svenningsson A; Andersson M; Olsson T
Review: LAKARTIDNINGEN. 1998;95(49):5623-5630
[Treatment of multiple sclerosis--1. New drugs may be effective but there still are frequent relapses].
Svenningsson A; Andersson M; Olsson T
Conference publication: NEUROLOGY. 1991;41(2):197-202
THE ROLE OF HTLV IN HIV-1 NEUROLOGIC DISEASE
BERGER JR; RAFFANTI S; SVENNINGSSON A; MCCARTHY M; SNODGRASS S; RESNICK L
Show more

Grants

RItuximab Long-Term DOSE Trial in Multiple Sclerosis – RIDOSE-MS. A randomized trial of long-term dosage of rituximab in multiple sclerosis
Swedish Research Council
1 December 2020 - 31 December 2024
Imatinib for multiple sclerosis relapses
Swedish Research Council
1 January 2018 - 31 December 2020
Randomized phase 3 trial comparing rituximab with dimethyl fumarate in newly diagnosed multiple sclerosis - RIFUND-MS
Swedish Research Council
1 January 2017 - 31 December 2019

Employments

Professor/Senior Physician, Department of Clinical Sciences, Danderyd Hospital, Karolinska Institutet, 2023-

Degrees and Education

Docent, Karolinska Institutet, 2001

Articles

All other publications

Grants

Employments

Degrees and Education

News from KI

Events from KI